Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.

Front Immunol · 2024 · PMC11026587 · PMID 38646542

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, it is worth noting that in the CheckMate-816 and CheckMate-77T trials, patients who did not achieve pCR all showed a trend of EFS benefit, but there was no statistical difference.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.